Biotherapies & Bioproduction: The MabDesign–Bpifrance Study Is Now Available
Biotherapies and bioproduction are profoundly transforming the life sciences sector, paving the way for more targeted and personalized treatments. On 18 November, the Hub’s Look’Up session presented the key findings of the study “Biotherapies & Bioproduction in France: Overview and Perspectives”, conducted by MabDesign and Bpifrance.
A panorama confirming a major turning point for the sector
As the first report of its kind, it provides a consolidated overview of the national biopharmaceutical ecosystem, combining market analysis, therapeutic pipeline insights, emerging technologies, industrial structuring and financial trends.
A rapidly accelerating global market
Biopharmaceuticals — including therapeutic antibodies, cell therapies, gene therapies, mRNA technologies and exosomes — are now a major driver of growth for the global pharmaceutical industry.
France is well positioned but faces a scale-up challenge
With a solid and diverse national pipeline, France stands out for its strong scientific expertise.
However, industrial scaling, infrastructure financing, access to specialized skills and increased production capacity remain critical challenges for strengthening health sovereignty.
A sector that is taking shape but needs to accelerate
The report highlights the need to strengthen production capabilities, develop industrial partnerships, reinforce workforce skills and expand collaborative projects to meet the growing demand for innovative therapies.
Strong trends expected for 2024–2025
– Expansion of advanced new biopharmaceutical classes (e.g., exosomes)
– Rising demand for bioproduction technologies
– Growing importance of public and private investment
– Emergence of key industrial players and notable French success stories
A strategic issue for health sovereignty
Strengthening France’s ability to develop and produce biopharmaceuticals is not only an economic priority but also essential to ensure access to innovative treatments and secure the value chain amid global pressures.
The study aligns fully with the ambitions of France 2030, which positions biotherapies and bioproduction as key national strategic priorities.